India’s small and mid-sized pharmaceutical companies are under pressure again.
This time, the pressure is coming from several directions at once: API dependence, solvent costs, packaging material prices, compliance expenses and global supply-chain disruptions.
Indian pharma MSMEs have warned that rising costs are squeezing margins and making it harder for smaller manufacturers to compete. The issue is not limited to finished drugs. It runs through the entire manufacturing chain.
APIs remain one of the biggest weak points.
India is often called the “pharmacy of the world,” but its pharmaceutical production still depends heavily on imported APIs and key starting materials, especially from China. That dependence becomes painful whenever prices rise, shipping slows, or geopolitical uncertainty increases.
Large drugmakers can manage this better.
They can hold more inventory, negotiate better contracts, diversify suppliers and absorb temporary cost increases.
Smaller companies do not have the same room.
When API prices move, they feel it quickly. When solvent prices rise, production costs rise. When PVC packaging material becomes more expensive, even basic drug packaging becomes harder to manage.
This is where the story becomes important for the global supply chain.
India’s competitiveness has long depended on efficient manufacturing and cost control. But if input costs keep rising, the advantage becomes harder to defend.
Cheap manufacturing is not automatic. It depends on stable upstream supply.
The pressure also comes at a time when regulators and buyers are asking for higher quality standards, better traceability and stronger compliance systems.
That means smaller companies face a double burden: higher material costs and higher compliance costs.
For the API market, this creates a clear signal.
India will keep trying to reduce import dependence, but building domestic API capacity takes time. It requires investment, environmental approvals, technology, scale and predictable demand.
Until then, Indian pharma manufacturers will remain exposed to upstream chemical and API volatility.
For global suppliers, this may create opportunity.
Indian buyers still need reliable APIs, intermediates, solvents, excipients and packaging materials. But they will also be more price-sensitive and more focused on supply security.
The companies that win will not simply be the cheapest.
They will be the ones that can offer stable supply, documentation support and predictable delivery.
